PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Daver, N. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Jabbour, E. [1 ]
Borthakur, G. [1 ]
Pierce, S. [1 ]
Vaughan, K. [1 ]
Vaughan, K. [1 ]
Ning, J. [2 ]
Gonzalez, G. [2 ]
Pemmarjau, N. [1 ]
Kadia, T. [1 ]
Konopleva, M. [1 ]
Andreeff, M. [1 ]
DiNardo, C. [1 ]
Cortes, J. [1 ]
Ward, R. [3 ]
Craig, A. [3 ]
Ravandi, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Sunesis Inc, San Francisco, CA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S505
引用
收藏
页码：187 / 188
页数：2
相关论文
共 50 条
  • [21] Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
    Roboz, Gail J.
    Ritchie, Ellen K.
    Dault, Yulia
    Lam, Linda
    Marshall, Danielle C.
    Cruz, Nicole M.
    Hsu, Hsiao-Ting C.
    Hassane, Duane C.
    Christos, Paul J.
    Ippoliti, Cindy
    Scandura, Joseph M.
    Guzman, Monica L.
    HAEMATOLOGICA, 2018, 103 (08) : 1308 - 1316
  • [22] Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
    Kirschbaum, Mark
    Gojo, Ivana
    Goldberg, Stuart L.
    Kujawski, Lisa
    Atallah, Ehab
    Marks, Peter
    Garcia-Vargas, Jose
    Rizvi, Syed
    Di Gravio, Donna
    Ahern, Janet
    Issa, Jean-Pierre
    BLOOD, 2008, 112 (11) : 1250 - 1250
  • [23] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
    Ong, Faustine
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Ohanian, Maro
    Konopleva, Marina
    Jabbour, Elias
    Jain, Nitin
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval
    Issa, Ghayas C.
    Sasaki, Koji
    Chien, Kelly S.
    Takahashi, Koichi
    Andreeff, Michael
    Muftuoglu, Muharrem
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Kantarjian, Hagop
    Cortes, Jorge E.
    Short, Nicholas
    BLOOD, 2022, 140 : 6206 - 6208
  • [25] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Bouligny, Ian M.
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Jain, Nitin
    Pemmaraju, Naveen
    Hammond, Danielle
    Chien, Kelly S.
    Takahashi, Koichi
    Issa, Ghayas C.
    Abbas, Hussein A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 735 - 736
  • [26] Mylotarg, fludarabine, ara-C and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [27] Final update of phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    Koller, Charles A.
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 136A - 136A
  • [28] MIDOSTAURIN (MIDO) DEMONSTRATES A FAVORABLE SAFETY PROFILE IN OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
    Fischer, T.
    Kantarjian, H.
    Feldman, E.
    Ehninger, G.
    Larson, P.
    Khan, M.
    Virkus, J.
    Stone, R.
    HAEMATOLOGICA, 2013, 98 : 30 - 30
  • [29] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [30] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
    Halpern, Anna B.
    Estey, Elihu H.
    Othus, Megan
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Chen, Tara L.
    Becker, Pamela S.
    Scott, Bart L.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Shadman, Mazyar
    Stirewalt, Derek L.
    Walter, Roland B.
    BLOOD, 2014, 124 (21)
12345